Skip to main content

Table 3 Adjusted estimates of risk reduction of the onset of each deterioration assessment for patients taking enzalutamide vs. placebo (inverted hazard ratios [HR] and 95% confidence intervals [CI])

From: Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Deterioration events Adjusted 1/HR 95% CI P value
Any worsening from baseline full health (EQ index = 1) 0.52 0.42–0.65 <0.0001
Any decrease in EQ-5D index 0.53 0.48–0.61 <0.0001
Any decrease in EQ-5D VAS 0.62 0.55–0.70 <0.0001
“Worsening” on PCHC 0.76 0.65–0.88 0.0003
Worsening in EQ-5D dimensions
 Mobility 0.87 0.68–1.10 0.2357
 Self-care 0.60 0.43–0.83 0.0019
 Usual Activities 0.85 0.70–1.03 0.1066
 Pain/Discomfort 0.57 0.47–0.68 <0.0001
 Anxiety/Depression 0.66 0.53–0.83 0.0003
  1. PCHC Paretian Classification of Health Change, VAS visual analogue scale
  2. Relative risk reduction and 95% CIs from Cox proportional hazards models adjusted by the following baseline factors: age, fatigue score, pain score, geographic region, and baseline EQ-5D index or corresponding dimension value